EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
HCR Wealth Advisors Has $593,000 Holdings in Bristol-Myers Squibb (NYSE:BMY)
8,620 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Contravisory Investment Management Inc.
Bristol Myers Squibb discloses new IKZF1-4 degraders | BioWorld
SS&H Financial Advisors Inc. Boosts Stake in Bristol-Myers Squibb (NYSE:BMY)
Bristol Myers Squibb: Schizophrenia drug Cobenfy could treat Alzheimer's
Meyer Handelman Co. Sells 10,723 Shares of Bristol-Myers Squibb (NYSE:BMY)
Radnor Capital Management LLC Reduces Stake in Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb (NYSE:BMY) Stock Position Increased by 626 Financial LLC
Acropolis Investment Management LLC Has $1.92 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Marcum Wealth LLC
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Wright Investors Service Inc.
FNY Investment Advisers LLC Acquires 12,360 Shares of Bristol-Myers Squibb (NYSE:BMY)
Friedenthal Financial Acquires Shares of 879 Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb (NYSE:BMY) Stake Raised by Brookstone Capital Management
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment
Bristol-Myers Squibb (NYSE:BMY) Stake Reduced by Burns J W & Co. Inc. NY
Courier Capital LLC Sells 4,607 Shares of Bristol-Myers Squibb (NYSE:BMY)
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - January 14, 2025 - Zacks.com
Burns J W & Co. Inc. NY Has $1.85 Million Position in Bristol-Myers Squibb (NYSE:BMY)
Mid American Wealth Advisory Group Inc. Lowers Stock Position in Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb Co (BMY) Strengthens Collaboration with ArsenalBio for Advanced T Cell ...
Capital Investment Advisors LLC Has $14.02 Million Stake in Bristol-Myers Squibb (NYSE:BMY)
CAR T Cell Therapy Breyanzi® (lisocabtagene maraleucel) Approved for Second-Line Relapsed or Refractory Diffuse Large B-cell Lymphoma
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors | The Manila Times
-- Bristol Myers Squibb exercises an exclusive license optio
ArsenalBios Says Bristol Myers Squibb Exercises Exclusive License Option For AB-4000 Series Programs
Bristol Myers Squibb licenses new CAR T therapy By Investing.com
Other news to note for Jan. 13, 2025 | BioWorld
Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY) | Markets Insider
Graypoint LLC Buys 4,705 Shares of Bristol-Myers Squibb (NYSE:BMY)
West Oak Capital LLC Has $2.28 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)
Atlas Brown Inc. Acquires 518 Shares of Bristol-Myers Squibb (NYSE:BMY)
Sage Capital Advisors llc Buys 567 Shares of Bristol-Myers Squibb (NYSE:BMY)
Recognition underscores BMS' continued commitment to innovat
Franklin Street Advisors Inc. NC Boosts Stock Position in Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb (NYSE:BMY) Shares Acquired Rep. Virginia Foxx
International Assets Investment Management LLC Cuts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade - January 9, 2025 - Zacks.com
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Douglas Lane & Associates LLC
114,649 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by InvesTrust
Truist Financial Issues Positive Forecast for Bristol-Myers Squibb (NYSE:BMY) Stock Price
Bristol-Myers stock backed by Buy rating as mega-blockbuster potential unfolds By Investing.com
Bristol-Myers Squibb (NYSE:BMY) Given Consensus Rating of "Hold" by Analysts
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
Range Financial Group LLC Buys 43,495 Shares of Bristol-Myers Squibb (NYSE:BMY)
Cambridge Cognition's CANTAB aids in schizophrenia drug approval By Investing.com
Bath Savings Trust Co Sells 400 Shares of Bristol-Myers Squibb (NYSE:BMY)
Bangor Savings Bank Cuts Stake in Bristol-Myers Squibb (NYSE:BMY)
GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27) By Reuters
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Bangor Savings Bank
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by CWA Asset Management Group LLC
Bard Financial Services Inc. Has $2.23 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Pensionfund Sabic Boosts Stake in Bristol-Myers Squibb (NYSE:BMY)
H.C. Wainwright reaffirms Buy rating on Alumis stock following Bristol-Myer's PsA data By Investing.com
Nordea Investment Management AB Sells 815,575 Shares of Bristol-Myers Squibb (NYSE:BMY)
The Evidence Gap: Immunotherapy Timing in Early-Stage NSCLC? | MDedge
Q3 EPS Estimate for Bristol-Myers Squibb Lifted by Analyst
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
Global Companies Sold a Record $8 Trillion of Bonds Last Year - Markets Insider
Q3 EPS Estimate for Bristol-Myers Squibb Boosted by Analyst
Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference By Investing.com
Traders Purchase High Volume of Bristol-Myers Squibb Call Options (NYSE:BMY)
FDA Approves Subcutaneous Form of Bristol Myers Squibb's Opdivo Qvantig for Multiple Solid Tumor Indications
Bristol-Myers Squibb (NYSE:BMY) Short Interest Update
2025 Trends Buoying Boom Phase in APAC
Profits slide at main Irish unit of drug giant Bristol Myers Squibb
Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024?
Bristol-Myers Squibb (NYSE:BMY) Share Price Crosses Above 200-Day Moving Average - Here's Why
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?
Long-Term Stock Portfolio: Best Stocks for 10 Years
Piper Sandler supports Century shares with Overweight rating as CAR-iNK study progresses By Investing.com
Halozyme stock rated Buy after FDA approval for SC Opdivo with ENHANZE tech By Investing.com
Bristol-Myers Squibb's SWOT analysis: navigating challenges in biopharma stock By Investing.com
Halozyme Says FDA Approved Bristol Myers's Opdivo Qvantig With ENHANZE For Subcutaneous Use
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo By Reuters
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications By Investing.com
Bristol Myers Squibb patents IKZF1-4 degradation inducers | BioWorld
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY) | Markets Insider
Health: FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
Bristol Myers Squibb Receives FDA Approval for Cancer Treatment | Morningstar
Bargain hunting: These 8 portfolio stocks look quite cheap, but only some are worth buying
Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors | Markets Insider
Myelodysplastic Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight
US FDA approves injectable form of Bristol Myers' Opdivo By Reuters
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
Bristol Myers Squibb (BMY) Stock Moves -0.55%: What You Should Know - December 27, 2024 - Zacks.com
Latest news
Bitcoin Price Action Muted: A Complete Guide on How to Buy Bitcoins in the UK
Week Ahead: Japanese CPI and the BoJ rate hike on the watch, All eyes on the Canada inflation and Trump inauguration
